Literature DB >> 3788803

Predicting the extent and location of coronary artery disease in acute myocardial infarction by echocardiography during dobutamine infusion.

C Berthe, L A Pierard, M Hiernaux, G Trotteur, P Lempereur, J Carlier, H E Kulbertus.   

Abstract

The feasibility, safety and usefulness of 2-dimensional echocardiography (2-D echo) during dobutamine infusion for identifying patients with multivessel coronary artery disease (CAD) after acute myocardial infarction (AMI) were evaluated in 30 patients 5 to 10 days after AMI. Patients underwent 2-D echo under basal conditions and during dobutamine infusion at each dose from 5 to a maximum of 40 micrograms/kg/min, limited multilead submaximal bicycle exercise testing and coronary and left ventricular angiography. Echocardiograms were analyzed independently by 2 observers. The test response was considered positive if abnormal wall motion and reduced myocardial thickening were observed during dobutamine infusion in vascular distributions other than the area of infarction identified during basal conditions. Exercise testing was considered positive when more than 1 mm of ST depression occurred 80 ms after the J point. Dobutamine stress testing was well tolerated; no complications and no significant arrhythmia were observed. Echocardiographic recordings were adequate in all patients during the entire test; the concordance in interpretation between the 2 observers was perfect for the prediction and location of ischemic segments during dobutamine infusion. In 15 of 17 patients without multivessel CAD, no asynergy was observed outside the infarct zone during dobutamine infusion (specificity 88%). In 11 of 13 patients with multivessel CAD, new wall motion abnormalities were identified in the segments corresponding to the arterial lesions diagnosed by angiography (sensitivity 85%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3788803     DOI: 10.1016/0002-9149(86)90376-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Myocardial oxidative metabolism in normal subjects in fasting, glucose loading and dobutamine infusion states.

Authors:  N Tamaki; Y Magata; N Takahashi; M Kawamoto; T Torizuka; Y Yonekura; S Nishizawa; N Sadato; E Tadamura; S Ono
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

2.  Metabolic reserve in normal myocardium assessed by positron emission tomography with C-11 palmitate.

Authors:  N Tamaki; M Kawamoto; N Takahashi; Y Yonekura; Y Magata; R Nohara; H Kambara; C Kawai; J Konishi
Journal:  Ann Nucl Med       Date:  1991-07       Impact factor: 2.668

3.  Time-course of dobutamine-induced wall motion abnormalities in the infarct area following thrombolytic therapy.

Authors:  R Bigi; G Curti; C Sponzilli; D Castini; G Occhi; C Fiorentini
Journal:  Int J Card Imaging       Date:  1998-12

Review 4.  Comparison of approaches in the assessment of myocardial viability and follow-up of PTCA/CABG. The role of echocardiography.

Authors:  L A Piérard
Journal:  Int J Card Imaging       Date:  1993

5.  Oxidative metabolism in the myocardium in normal subjects during dobutamine infusion.

Authors:  N Tamaki; Y Magata; N Takahashi; M Kawamoto; T Torizuka; Y Yonekura; E Tadamura; K Okuda; S Ono; R Nohara
Journal:  Eur J Nucl Med       Date:  1993-03

6.  Serial assessment of left ventricular function during dobutamine stress by means of electrocardiography-gated myocardial SPECT: combination with dual-isotope myocardial perfusion SPECT for detection of ischemic heart disease.

Authors:  S Kumita ; K Cho; H Nakajo; M Toba; T Kijima; S Mizumura; T Oshina; T Kumazaki; J Sano; K Sakurai; K Munakata
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

7.  Relation between ST segment elevation during dobutamine stress test and myocardial viability after a recent myocardial infarction.

Authors:  A Elhendy; J H Cornel; J R Roelandt; R T van Domburg; M I Geleijnse; P R Nierop; J J Bax; A Sciarra; M M Ibrahim; M el-Refaee; G M el-Said; P M Fioretti
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

Review 8.  Dobutamine stress echocardiography: safety in diagnosing coronary artery disease.

Authors:  F Lattanzi; E Picano; E Adamo; A Varga
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

9.  Dobutamine stress echocardiography versus quantitative technetium-99m sestamibi SPECT for detecting residual stenosis and multivessel disease after myocardial infarction.

Authors:  P Lancellotti; T Benoit; P Rigo; L A Pierard
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

10.  The elusive link between coronary lesion morphology and dobutamine stress echocardiography results. The EDIC (Echo Dobutamine International Cooperative) Study Group.

Authors:  J Heyman; P Salvadé; E Picano; A Varga; E Gliozheni; R Sicari; M Previtali; G Rovelli
Journal:  Int J Card Imaging       Date:  1997-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.